EMRELIS™ Naming for NSCLC Therapy
A leading global pharmaceutical company partnered with Brandsymbol to develop a strategic name for a first-in-class treatment targeting advanced non-small cell lung cancer (NSCLC) with high c-Met protein overexpression—a population with historically poor prognosis and limited treatment options. This antibody-drug conjugate (ADC) represents a significant step forward in biomarker-driven oncology, offering a targeted therapeutic option where few exist.
The challenge was to create a name that captured the innovation and scientific advancement behind the therapy, while meeting global regulatory requirements and aligning with the pharmaceutical company’s oncology portfolio. Brandsymbol collaborated closely with the company’s stakeholders to generate, evaluate, and refine name candidates that conveyed efficacy, precision, and hope.
The result was EMRELISTM—a name that signals medical progress and strength. Leveraging the creative direction of an eagle, with attributes of precision and targeting, and a focus on lessening symptoms, EMRELISTM strengthens the pharmaceutical company’s position in the oncology space and marks a critical milestone in its commitment to developing targeted therapies for patients with unmet needs.
This successful partnership reflects our extensive experience in pharmaceutical branding, where our proprietary i4 methodology—Investigate, Inform, Inspire and Integrate—guides every step of the naming process to ensure strategic, regulatory, and market alignment.